Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

AIMS: In vitro studies indicated CYP3A4 alone was responsible for tolvaptan metabolism. To determine the effect of a CYP3A4 inhibitor (ketoconazole) and a CYP3A4 inducer (rifampicin) on tolvaptan pharmacokinetics (PK) and pharmacodynamics (PD), two clinical trials were performed. METHODS: For CYP3A4...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Shoaf, Susan E, Bricmont, Patricia, Mallikaarjun, Suresh
Format: Artigo
Sprog:Inglês
Udgivet: Blackwell Science Inc 2012
Fag:
Pharmacokinetic Dynamic Relationships
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3376434/
https://ncbi.nlm.nih.gov/pubmed/21988334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.04114.x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker